COVID-19: A new challenge for ECMO
Authors:
- 7 January 2021
- journal article
- research article
- Published by SAGE Publications in Perfusion
- Vol. 36 (6) , 573-574
Abstract
COVID results in a variety of pathophysiology that causes cardiorespiratory and the need for ECMO. These include hypoxic respiratory failure, cardiogenic shock, cardiac arrest, multisystem inflammatory disease, and vascular thrombosis with pulmonary embolism. A variety of cannulation strategies are required and the “hyperinflammation” and consequent coagulation abnormalities mandate new strategies to provide optimal ECMO support.Keywords
This publication has 6 references indexed in Scilit:
- Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort studyThe Lancet Respiratory Medicine, 2020
- Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registryThe Lancet, 2020
- COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York CityLaboratory Investigation, 2020
- Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumoniaJournal of Thrombosis and Haemostasis, 2020
- Safety of nitric oxide added to the ECMO circuit: a pilot study in childrenPerfusion, 2017
- Recent advances in thromboresistant and antimicrobial polymers for biomedical applications: just say yes to nitric oxide (NO)Biomaterials Science, 2016